In this review, we focus on the “favorable” and “unfavorable” gut microbiota in preclinical and clinical studies related to NSCLC immunotherapy, particularly anti-PD-1/PD-L1 therapy, and the impact of ATBs and dietary interventions on the efficacy of NSCLC immunotherapy (Figure 1). Here, CD274 is linked to non-small cell lung carcinoma.